Back to top
more

MacroGenics (MGNX)

(Real Time Quote from BATS)

$1.58 USD

1.58
56,842

-0.03 (-1.86%)

Updated Aug 7, 2025 12:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ImmunoGen (IMGN) Q2 Earnings and Sales Beat, Shares Down

by Zacks Equity Research

ImmunoGen (IMGN) reports encouraging second-quarter results. Top-line data from pivotal study on its lead candidate, mirvetuximab soravtansine, likely to be delayed by six to eight weeks.

Zacks Equity Research

MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of -6.82% and 42.78%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: MacroGenics (MGNX) Q2 Earnings Expected to Decline

by Zacks Equity Research

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Are Options Traders Betting on a Big Move in MacroGenics (MGNX) Stock?

by Zacks Equity Research

Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.

Zacks Equity Research

MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of 9.90% and 84.12%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Ritujay Ghosh headshot

Trump Pushes for US-Made Medical Products: 4 Winners

by Ritujay Ghosh

An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.

Zacks Equity Research

ImmunoGen (IMGN) Q1 Earnings and Sales Miss, Shares Down

by Zacks Equity Research

ImmunoGen (IMGN) reports dismal first-quarter results.

Zacks Equity Research

Agios' (AGIO) Q1 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Agios' (AGIO) loss and revenues better estimates in Q1. The company's wholly owned leukemia drug Tibsovo sees a sequential rise in sales.

Zacks Equity Research

MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of 12.68% and 134.54%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of 4.21% and -19.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

3 Medical Product Stocks Likely to Beat This Earnings Season

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Zacks Equity Research

MacroGenics (MGNX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

MacroGenics (MGNX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of 32.29% and -39.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab

by Zacks Equity Research

Incyte (INCY) inks a licensing deal with Zai Lab to develop and commercialize INCMGA0012 for hematology and oncology indications in Greater China.

Zacks Equity Research

Implied Volatility Surging for MacroGenics (MGNX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.

Zacks Equity Research

MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of -4.21% and -15.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Frontier Communications' (FTR) Q4 Earnings: What's in Store?

by Zacks Equity Research

Soft demand pattern in voice and video businesses, along with decline in switched access are likely to take a toll on Frontier Communications' (FTR) fourth-quarter revenues.

Zacks Equity Research

Key Factors to Know Ahead of TransEnterix (TRXC) Q4 Earnings

by Zacks Equity Research

TransEnterix (TRXC) is anticipated to witness robust top-line growth in Q4 on the back of multiple product developments.

Zacks Equity Research

Will Leasing Support SBA Communications' (SBAC) Q4 Earnings?

by Zacks Equity Research

Solid domestic site leasing business, excellent services and cost control initiatives are likely to drive SBA Communications' (SBAC) fourth-quarter earnings.

Zacks Equity Research

HMS Holdings (HMSY) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

HMS Holdings (HMSY) expects to gain from its total population management or TPM business in fourth-quarter 2018.

Zacks Equity Research

What's in Store for Telefonica Brasil (VIV) in Q4 Earnings?

by Zacks Equity Research

Telefonica Brasil's (VIV) fourth-quarter earnings are likely to benefit from its asset base and solid position in key high-value segments.

Zacks Equity Research

Key Factors Likely to Shape CVS Health's (CVS) Q4 Earnings

by Zacks Equity Research

CVS Health (CVS) expects drug price inflation, product launches and higher utilization to fuel growth in Q4.

Zacks Equity Research

Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

by Zacks Equity Research

Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

Zacks Equity Research

Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?

by Zacks Equity Research

Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.

Zacks Equity Research

Will Diagnostics Business Ail LabCorp (LH) in Q4 Earnings?

by Zacks Equity Research

LabCorp (LH) is likely to gain traction from the company's collaboration with Walgreens.